Detailed Information

Cited 0 time in webofscience Cited 6 time in scopus
Metadata Downloads

Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study

Authors
Park, Se YoonJung, Joo HeeKwon, HyunwookShin, SungKim, Young HoonChong, Yong-PhilLee, Sang-OhChoi, Sang-HoKim, Yang SooWoo, Jun HeeKim, Sung-HanHan, Duck Jong
Issue Date
Apr-2020
Publisher
Blackwell Publishing Inc.
Keywords
cytomegalovirus; Pneumocystis jirovecii pneumonia; rejection
Citation
Transplant Infectious Disease, v.22, no.2
Journal Title
Transplant Infectious Disease
Volume
22
Number
2
URI
https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2983
DOI
10.1111/tid.13245
ISSN
1398-2273
1399-3062
Abstract
Background Pneumocystis jirovecii pneumonia (PCP) is an important cause of morbidity and mortality in kidney transplant recipients (KTRs), and prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) is recommended. The aim of this study was to investigate incidence and risk factors for PCP in KTRs after 6-month TMP-SMX prophylaxis. Methods We conducted a case-control study of patients with PCP who received 6-month PCP prophylaxis with TMP-SMX after kidney transplantation (KT). In cases of rejection, PCP prophylaxis was provided for six additional months after anti-rejection therapy. Cytomegalovirus (CMV) infection was not considered an indication for PCP prophylaxis due to concerns of nephrotoxicity associated with TMP-SMX. Results Among 3941 kidney or pancreas-kidney transplant recipients, 67 (1.7%) developed PCP after discontinuing TMP-SMX. A total of 47 patients with KT PCP and 94 controls were included. Duration of PCP prophylaxis was similar between cases and controls (median 6 months, P = .53). In multivariate analysis, rejection (OR 3.9; 95% CI 1.4-11.1) and CMV infection (OR 2.4; 95% CI 1.0-5.8) were independently associated with PCP development after TMP-SMX. Rejection or CMV infection was observed in 70% of patients with PCP. Time to PCP development after rejection (median [IQR] 6 [5-19] months) was slightly shorter than after CMV infection (median [IQR] 9 [5-12] months; P = .18). Conclusion Post-prophylaxis PCP occurred in <2% of KTRs, and about two-thirds of these experienced rejection or CMV infection. These data suggest that at least 6 to 9-month additional chemoprophylaxis may be needed to prevent PCP in KTRs with transplant rejection or CMV infection.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Internal Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE